Sustained systemic response paralleled with ovarian metastasis progression by sunitinib in metastatic renal cell carcinoma: Is this an anti-angiogenic potentiation of cancer?

about

Sustained systemic response paralleled with ovarian metastasis progression by sunitinib in metastatic renal cell carcinoma: Is this an anti-angiogenic potentiation of cancer?

Item

http://www.wikidata.org/entity/Q35898650

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Sustained systemic response pa ...... ogenic potentiation of cancer?

@ast

Sustained systemic response pa ...... ogenic potentiation of cancer?

@en

type

Item

label

Sustained systemic response pa ...... ogenic potentiation of cancer?

@ast

Sustained systemic response pa ...... ogenic potentiation of cancer?

@en

prefLabel

Sustained systemic response pa ...... ogenic potentiation of cancer?

@ast

Sustained systemic response pa ...... ogenic potentiation of cancer?

@en

P1476

Sustained systemic response pa ...... ogenic potentiation of cancer?

@en

P2093

Dig Vijay Singh

http://www.w3.org/2001/XMLSchema#string

Nandita Kakkar

http://www.w3.org/2001/XMLSchema#string

Uttam K Mete

http://www.w3.org/2001/XMLSchema#string

P2860

Modes of resistance to anti-angiogenic therapy

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

Radiologic measurements of tumor response to treatment: practical approaches and limitations.

Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy.

Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway.

Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors.

A differential response to sunitinib: sustained systemic response paralleled by intra-dural progression in the spine. Should standard response criteria be reviewed?

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.

P304

387-390

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.4103/0974-7796.153669

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26229334

http://www.w3.org/2001/XMLSchema#string

P932

4518383

http://www.w3.org/2001/XMLSchema#string